This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Chr. Hansen Holding Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Chr. Hansen Holding.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Chemicals kazanç büyümesi	22.6%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	14.8%
Analist kapsamı	Low
Son güncelleme	15 Dec 2023

Gelecekteki son büyüme güncellemeleri

Recent updates

Be Wary Of Chr. Hansen Holding (CPH:CHR) And Its Returns On Capital

Dec 31

Is Chr. Hansen Holding (CPH:CHR) Using Too Much Debt?

Dec 13

Chr. Hansen Holding (CPH:CHR) Will Be Hoping To Turn Its Returns On Capital Around

Jun 26

These 4 Measures Indicate That Chr. Hansen Holding (CPH:CHR) Is Using Debt Reasonably Well

May 21

Chr. Hansen Holding (CPH:CHR) Could Be Struggling To Allocate Capital

Mar 28

Chr. Hansen Holding's (CPH:CHR) Shareholders Will Receive A Bigger Dividend Than Last Year

Nov 14

Chr. Hansen Holding (CPH:CHR) Is Paying Out A Larger Dividend Than Last Year

Oct 29

Chr. Hansen Holding (CPH:CHR) Is Increasing Its Dividend To €7.04

Oct 15

Here's What's Concerning About Chr. Hansen Holding's (CPH:CHR) Returns On Capital

Sep 13

These 4 Measures Indicate That Chr. Hansen Holding (CPH:CHR) Is Using Debt Reasonably Well

Aug 29

There Are Reasons To Feel Uneasy About Chr. Hansen Holding's (CPH:CHR) Returns On Capital

Mar 06

Does Chr. Hansen Holding (CPH:CHR) Have A Healthy Balance Sheet?

Feb 19

Kazanç ve Gelir Büyüme Tahminleri

CPSE:CHR - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (EUR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
8/31/2026	1,573	341	267	452	4
8/31/2023	1,334	227	180	317	N/A
5/31/2023	1,310	229	171	320	N/A
2/28/2023	1,294	229	133	276	N/A
11/30/2022	1,259	228	128	270	N/A
8/31/2022	1,218	225	167	309	N/A
5/31/2022	1,183	230	191	327	N/A
2/28/2022	1,146	221	228	354	N/A
11/30/2021	1,102	209	233	352	N/A
8/31/2021	1,077	199	155	311	N/A
5/31/2021	1,038	199	169	318	N/A
2/28/2021	1,014	213	208	358	N/A
11/30/2020	994	222	224	374	N/A
8/31/2020	970	232	246	365	N/A
5/31/2020	798	218	280	369	N/A
2/29/2020	844	221	223	326	N/A
11/30/2019	888	224	212	324	N/A
8/31/2019	937	229	180	299	N/A
5/31/2019	1,152	246	174	306	N/A
2/28/2019	1,132	240	190	313	N/A
11/30/2018	1,112	233	181	295	N/A
8/31/2018	1,097	228	195	302	N/A
5/31/2018	1,084	226	164	271	N/A
2/28/2018	1,080	224	168	270	N/A
11/30/2017	1,075	224	181	286	N/A
8/31/2017	1,063	224	178	284	N/A
5/31/2017	1,035	212	N/A	290	N/A
2/28/2017	1,007	205	N/A	260	N/A
11/30/2016	976	192	N/A	246	N/A
8/31/2016	949	184	N/A	245	N/A
5/31/2016	927	179	N/A	226	N/A
2/29/2016	905	174	N/A	237	N/A
11/30/2015	885	172	N/A	239	N/A
8/31/2015	859	163	N/A	222	N/A
5/31/2015	830	150	N/A	205	N/A
2/28/2015	800	141	N/A	188	N/A
11/30/2014	773	133	N/A	178	N/A
8/31/2014	756	132	N/A	176	N/A
5/31/2014	745	145	N/A	174	N/A
2/28/2014	738	142	N/A	182	N/A
11/30/2013	731	135	N/A	186	N/A
8/31/2013	738	138	N/A	190	N/A
5/31/2013	730	126	N/A	185	N/A
2/28/2013	719	125	N/A	175	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if CHR's forecast earnings growth is above the savings rate (0.7%).

Kazançlar ve Piyasa: Insufficient data to determine if CHR's earnings are forecast to grow faster than the Danish market

Yüksek Büyüme Kazançları: Insufficient data to determine if CHR's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if CHR's revenue is forecast to grow faster than the Danish market.

Yüksek Büyüme Geliri: Insufficient data to determine if CHR's revenue is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CHR's Return on Equity is forecast to be low in 3 years time (14.8%).

This company is no longer active

Chr. Hansen Holding Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Chr. Hansen Holding A/S Provides Earnings Guidance for the Period September 1, 2022 – August 31, 2023

Chr. Hansen Holding A/S Provides Revenue Guidance for 2022/23

Chr. Hansen Holding A/S Provides Earnings Guidance for the Full Year of Fiscal 2022

Recent updates

Chr. Hansen Holding A/S(CPSE:CHR) dropped from FTSE All-World Index (USD)

New major risk - Revenue and earnings growth

Chr. Hansen Holding A/S(CPSE:CHR) dropped from OMX Copenhagen 20 Index

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Chr. Hansen Holding A/S to Report Fiscal Year 2024 Results on Feb 06, 2025

Be Wary Of Chr. Hansen Holding (CPH:CHR) And Its Returns On Capital

Is Chr. Hansen Holding (CPH:CHR) Using Too Much Debt?

Full year 2023 earnings: EPS misses analyst expectations

Chr. Hansen Holding A/S Declares Interim Dividend for the Period September 1, 2022 to August 31, 2023, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Chr. Hansen Holding A/S Provides Earnings Guidance for the Period September 1, 2022 – August 31, 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Chr. Hansen Holding (CPH:CHR) Will Be Hoping To Turn Its Returns On Capital Around

These 4 Measures Indicate That Chr. Hansen Holding (CPH:CHR) Is Using Debt Reasonably Well

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chr. Hansen Holding (CPH:CHR) Could Be Struggling To Allocate Capital

Executive VP recently bought kr.555k worth of stock

First quarter 2023 earnings: EPS misses analyst expectations

Chr. Hansen Holding A/S Provides Revenue Guidance for 2022/23

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Investor sentiment improved over the past week

Chr. Hansen Holding A/S Approves Ordinary Dividend

Upcoming dividend of kr.7.04 per share

High number of new directors

Chr. Hansen Holding's (CPH:CHR) Shareholders Will Receive A Bigger Dividend Than Last Year

Chr. Hansen Holding A/S to Report Q1, 2023 Results on Dec 12, 2022

Chr. Hansen Holding (CPH:CHR) Is Paying Out A Larger Dividend Than Last Year

Investor sentiment improved over the past week

Chr. Hansen Holding (CPH:CHR) Is Increasing Its Dividend To €7.04

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Chr. Hansen Holding A/S Proposes Ordinary Dividend for 2021/22

Here's What's Concerning About Chr. Hansen Holding's (CPH:CHR) Returns On Capital

These 4 Measures Indicate That Chr. Hansen Holding (CPH:CHR) Is Using Debt Reasonably Well

A Look At The Intrinsic Value Of Chr. Hansen Holding A/S (CPH:CHR)

Chr. Hansen Holding A/S to Report Q2, 2023 Results on Apr 13, 2023

Third quarter 2022 earnings: EPS misses analyst expectations

Chr. Hansen Holding A/S Provides Earnings Guidance for the Full Year of Fiscal 2022

Capital Allocation Trends At Chr. Hansen Holding (CPH:CHR) Aren't Ideal

Chr. Hansen Holding (CPH:CHR) Seems To Use Debt Quite Sensibly

A Look At The Fair Value Of Chr. Hansen Holding A/S (CPH:CHR)

High number of new directors

Chr. Hansen Announces Lillie Li Valeur Steps Down from the Board of Directors

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

There Are Reasons To Feel Uneasy About Chr. Hansen Holding's (CPH:CHR) Returns On Capital

Does Chr. Hansen Holding (CPH:CHR) Have A Healthy Balance Sheet?

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin